SCHEMBL3021877

SCHEMBL3021877

OCCOc1cc(C(F)(F)F)ccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.46
NOS2 P35228 1/20 0.46
NPC1 O15118 1/20 0.43
CASP3 P42574 1/20 0.43
RAB9A P51151 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ADRB2 P07550 1/20 0.39
HTR1A P08908 1/20 0.39
ABL1 P00519 1/20 0.38
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
CYP19A1 P11511 1/20 0.38
RAF1 P04049 5/20 0.37
BRAF P15056 1/20 0.37
CTSS P25774 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19732851 0.83 NOS3 (0.50) NOS3NOS2NPC1CASP3RAB9A
SCHEMBL13145718 0.83 SMN1; SMN2 (0.39) ALDH1A1L3MBTL1ABL1CHEK1
SCHEMBL15471437 0.83 NOS3 (0.46) NOS3NOS2NPC1CASP3RAB9A
SCHEMBL15464568 0.81 ADRB2 (0.42) NOS3NOS2NPC1CASP3RAB9A
SCHEMBL3661833 0.81 AR (0.40) NPC1CASP3RAB9ASENP8SENP7
SCHEMBL3661836 0.81 CYP3A4 (0.36) NPC1CASP3RAB9ASENP8SENP7
SCHEMBL15465000 0.80 ADRB2 (0.41) NOS3NOS2NPC1CASP3RAB9A
SCHEMBL4688748 0.80 NOS3 (0.44) NOS3NOS2NPC1CASP3RAB9A
SCHEMBL28746485 0.79 L3MBTL1 (0.43) NOS3NOS2NPC1CASP3RAB9A
SCHEMBL3149643 0.79 NOS3 (0.48) NOS3NOS2NPC1CASP3RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2185562-B1 PYRROLOPYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES JANSSEN PHARMACEUTICA NV (BE) 2015-12-02 EP disclosed
US-8318731-B2 Pyrrolopyrimidines JANSSEN PHARMACEUTICA NV (BE) 2012-11-27 US disclosed
US-20100204197-A1 PYRROLOPYRIMIDINES JANSSEN PHARMACEUTICA NV (BE) 2010-08-12 US disclosed
EP-2185562-A1 PYRROLOPYRIMIDINES Janssen Pharmaceutica, N.V. (BE) 2010-05-19 EP disclosed
WO-2009016132-A1 PYRROLOPYRIMIDINES JANSSEN PHARMACEUTICA NV (BE) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204197-A1 PYRROLOPYRIMIDINES PLK4, PLK2, PLK3 NOS3 2440/4885NOS2 2317/4885NPC1 3454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.